Morgan Stanley Ambrx Biopharma Inc. Transaction History

Morgan Stanley

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	BUY	$9.3 - $16.6 $199,959 - $356,916	21,501 Added 700.36%	24,571 $282,000
Q2 2023 Aug 14, 2023	BUY	$7.66 - $16.46 $23,194 - $49,840	3,028 Added 7209.52%	3,070 $50,000
Q1 2023 May 15, 2023	BUY	$1.46 - $12.54 $61 - $526	42 New	42 $0
Q2 2022 Aug 15, 2022	SELL	$2.53 - $4.35 $7,083 - $12,179	-2,800 Closed	0 $0
Q1 2022 Oct 27, 2022	BUY	$4.07 - $9.0 $11,396 - $25,200	2,800 New	2,800 $12,000

Q3 2021 Nov 15, 2021	BUY	$13.31 - $22.53 $37,268 - $63,084	2,800 New	2,800 $38,000

31.2K

Ticker AMAM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,618,400
Market Cap $1.08B
Description
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gas...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.